Market Currents
Oppenheimer says that investors are drawing " JAZZ <font color="red">-0.4%</font>)...
-
Friday, September 28, 2012, 3:15 PM ETOppenheimer says that investors are drawing " JAZZ <font color="red">-0.4%</font>) Xyrem and Questcor's (QCOR) drug Acthar. Xyrem is very different from Acthar, the firm notes, and concerns over the drug's pricing and reimbursement are unwarranted. The firm maintains its $66 target and Outperform rating on the stock. ">inappropriate parallels " between Jazz Pharmaceutical's (JAZZ -0.4%) Xyrem and Questcor's (QCOR) drug Acthar. Xyrem is very different from Acthar, the firm notes, and concerns over the drug's pricing and reimbursement are unwarranted. The firm maintains its $66 target and Outperform rating on the stock.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 8 comments:
Huh?
Just ignore the text between " JAZZ... and ">, and the whole thing makes perfect sense.
Obviously, then, the target of 66 is for JAZZ (fat chance with QCOR :( ). Oppenheimer has a lot of nerve talking about "inappropriate parallels" between JAZZ's drug and QCOR's, considering they were the ones who pumped QCOR into the 60s they day before the Citron bomb dropped.